SAFETY DATA SHEET
according to GB/T 16483 and GB/T 1751

Imipenem / Cilastatin / Relebactam Formula-
tion

Version: 4.17  Revision Date: 2021/08/27  SDS Number: 67736-00023  Date of last issue: 2020/10/10
Revision Date: 2021/08/27  SDS Number: 67736-00023  Date of last issue: 2020/10/10

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Imipenem / Cilastatin / Relebactam Formulation

Manufacturer or supplier's details

Company : MSD
Address : 199 Wenhai North Road
           HEDA, Hangzhou - Zhejiang Province - CHINA  310018
Telephone : 908-740-4000
Emergency telephone number : 86-571-87268110
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

| Appearance | powder |
| Colour     | White to light yellow |
| Odour      | No data available |

Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

- Serious eye damage/eye irritation : Category 2A
- Respiratory sensitisation : Category 1
- Reproductive toxicity : Category 2
- Specific target organ toxicity - repeated exposure : Category 2
- Short-term (acute) aquatic hazard : Category 1
- Long-term (chronic) aquatic hazard : Category 1

GHS label elements
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 4.17  Revision Date: 2021/08/27  SDS Number: 67736-00023  Date of last issue: 2020/10/10
Date of first issue: 2015/02/27

Hazard pictograms:

Signal word: Danger

Hazard statements:
H319 Causes serious eye irritation.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements:

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P284 Wear respiratory protection.

Response:
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Causes serious eye irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.
Environmental hazards
Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>Chemical name: Cilastatin</td>
</tr>
<tr>
<td>Imipenem</td>
<td>Chemical name: Imipenem</td>
</tr>
<tr>
<td>Relebactam</td>
<td>Chemical name: Relebactam</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled
If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact
In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed
If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed
Causes serious eye irritation.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
Contact with dust can cause mechanical irritation or drying of the skin.
5. FIREFIGHTING MEASURES

- **Protection of first-aiders**: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

- **Notes to physician**: Treat symptomatically and supportively.

**Suitable extinguishing media**
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media**: None known.

**Specific hazards during firefighting**: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**
- Carbon oxides
- Metal oxides

**Specific extinguishing methods**
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for firefighters**
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

- **Personal precautions, protective equipment and emergency procedures**: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

- **Environmental precautions**: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

- **Methods and materials for containment and cleaning up**: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

Version 4.17  Revision Date: 2021/08/27  SDS Number: 67736-00023  Date of last issue: 2020/10/10  Date of first issue: 2015/02/27

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling
Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Do not get in eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage:
- Keep in properly labelled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>TWA</td>
<td>5 mg/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>TWA</td>
<td>1000 ug/m3 (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: RSEN
Imipenem / Cilastatin / Relebactam Formula- tion

Engineering measures: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Eye/face protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.
Hand protection: Chemical-resistant gloves

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>White to light yellow</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
### 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
<tr>
<td>Possibility of hazardous reactions</td>
<td>May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.</td>
</tr>
</tbody>
</table>

- Evaporation rate: Not applicable
- Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
- Flammability (liquids): Not applicable
- Upper explosion limit / Upper flammability limit: No data available
- Lower explosion limit / Lower flammability limit: No data available
- Vapour pressure: Not applicable
- Relative vapour density: Not applicable
- Relative density: No data available
- Density: No data available
- Solubility(ies): Water solubility: soluble
- Partition coefficient: n-octanol/water: Not applicable
- Auto-ignition temperature: No data available
- Decomposition temperature: No data available
- Viscosity
  - Viscosity, dynamic: No data available
  - Viscosity, kinematic: Not applicable
- Explosive properties: Not explosive
- Oxidizing properties: The substance or mixture is not classified as oxidizing.
- Molecular weight: No data available
- Particle size: No data available
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formulation

Version 4.17 Revision Date: 2021/08/27 SDS Number: 67736-00023 Date of last issue: 2020/10/10 Date of first issue: 2015/02/27

Conditions to avoid: Heat, flames and sparks.
Incompatible materials: Avoid dust formation.
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Cilastatin:
Acute oral toxicity: LD50 (Rat): > 10,000 mg/kg
LD50 (Mouse): > 10,000 mg/kg

Imipenem:
Acute oral toxicity: LD50 (Mouse): 10,000 mg/kg

Acute toxicity (other routes of administration): LD50 (Rat): > 2,000 mg/kg
Application Route: Intravenous
LD50 (Mouse): 1,500 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:

Cilastatin:
Species: Rabbit
Result: No skin irritation

Relebactam:
Method: EpiDerm
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.
Imipenem / Cilastatin / Relebactam Formula-
tion

**Components:**

**Cilastatin:**
Species: Rabbit
Result: Moderate eye irritation

**Relebactam:**
Result: No eye irritation
Method: Bovine cornea (BCOP)

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:**

**Cilastatin:**
Exposure routes: Skin contact
Remarks: No data available
Remarks: Inhalation
Remarks: No data available

**Imipenem:**
Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.
Exposure routes: Skin contact
Remarks: Not classified due to lack of data.

**Relebactam:**
Test Type: Local lymph node assay (LLNA)
Exposure routes: Dermal
Result: Not a skin sensitizer.

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Cilastatin:**
Genotoxicity in vitro: Test Type: Microbial mutagenesis assay (Ames test)
Result: negative

**Imipenem:**
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.17</td>
<td>2021/08/27</td>
<td>67736-00023</td>
<td>2020/10/10</td>
<td>2015/02/27</td>
</tr>
</tbody>
</table>

Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Test system: Chinese hamster lung cells
  - Result: negative
- Test Type: reverse mutation assay
  - Result: negative
- Test Type: unscheduled DNA synthesis assay
  - Result: negative
- Test Type: Chromosomal aberration
  - Result: negative
- Test Type: sister chromatid exchange assay
  - Result: negative

Genotoxicity in vivo:
- Test Type: In vivo micronucleus test
  - Species: Mouse
  - Application Route: Intravenous
  - Result: negative

Relebactam:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
  - Test Type: Chromosome aberration test in vitro
    - Result: negative

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - Species: Rat
  - Application Route: Intraperitoneal injection
  - Result: negative

Germ cell mutagenicity - Assessment:
- Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity:
Not classified based on available information.

Reproductive toxicity:
Suspected of damaging the unborn child.

Components:

Cilastatin:
- Effects on fertility:
  - Test Type: Fertility/early embryonic development
    - Application Route: Intravenous
    - Fertility: LOAEL: 1,000
    - Symptoms: No adverse effects
    - Result: No effects on fertility and early embryonic development were detected.
Imipenem / Cilastatin / Relebactam Formula- 

Version 4.17  Revision Date: 2021/08/27  SDS Number: 67736-00023  Date of last issue: 2020/10/10  Date of first issue: 2015/02/27

Imipenem:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Intravenous  
Fertility: LOAEL: 80 mg/kg body weight  
Symptoms: No adverse effects, Reduced foetal weight  
Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Subcutaneous  
Fertility: LOAEL: 320 mg/kg body weight  
Symptoms: No adverse effects, Reduced foetal weight  
Result: No effects on fertility and early embryonic development were detected.

Effects on foetal development : Test Type: Development  
Species: Monkey  
Application Route: Intravenous  
Developmental Toxicity: LOAEL: 100 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: 60 mg/kg body weight  
Result: No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: 60 mg/kg body weight  
Result: No teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Relebactam:

Effects on fertility : Test Type: Pre-/postnatal development  
Species: Rat  
Application Route: Subcutaneous  
Fertility: NOAEL: 450 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal injection  
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight  
Result: No effects on foetal development
Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intraperitoneal injection  
Embryo-foetal toxicity: NOAEL: 450 mg/kg body weight  
Result: No effects on foetal development

Test Type: Development  
Species: Rat  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: >= 450 mg/kg body weight  
Result: No effects on fertility and early embryonic development were detected.

Test Type: Development  
Species: Rabbit  
Application Route: Intravenous  
Developmental Toxicity: NOAEL: 450 mg/kg body weight  
Result: No effects on foetal development

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Relebactam:**

Target Organs : Kidney  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Cilastatin:**

Species : Rat  
NOAEL : >= 500 mg/kg  
Application Route : Intravenous  
Exposure time : 90 Days  
Remarks : No significant adverse effects were reported

Species : Monkey  
NOAEL : >= 500 mg/kg  
Application Route : Intravenous  
Exposure time : 5 Weeks  
Remarks : No significant adverse effects were reported

**Imipenem:**

Species : Monkey
Imipenem / Cilastatin / Relebactam Formula-
tion

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>60 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

**Species**: Monkey

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>120 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Species**: Rat

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>180 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Species**: Rabbit

<table>
<thead>
<tr>
<th>LOAEL</th>
<th>150 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

**Species**: Rat, female

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>150 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

**Species**: Rat, male

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>450 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

**Species**: Monkey

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>25 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

**Species**: Monkey

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>37.5 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>30 d</td>
</tr>
</tbody>
</table>

**Species**: Monkey

<table>
<thead>
<tr>
<th>NOAEL</th>
<th>50 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Imipenem:
Inhalation: Symptoms: Nausea, Vomiting, Diarrhoea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash
Remarks: May cause sensitisation of susceptible persons by inhalation of aerosol or dust.

Relebactam:
Skin contact: Symptoms: Pain, Discomfort, Diarrhoea, Abdominal pain, insomnia, Nausea, sore throat, Vertigo

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cilastatin:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 99 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: EC50 (Anabaena flos-aquae): > 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): EC10 (Pimephales promelas (fathead minnow)): > 9.9 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Imipenem / Cilastatin / Relebactam Formula-
tion

Toxicity to daphnia and other aquatic invertebrates (Chron-
ic toxicity):
EC10 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Imipenem:
Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 78 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:
EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 0.002 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Pseudokirchneriella subcapitata (green algae)): > 74 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 74 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity):
100

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 9.4 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 11 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity):
10

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Relebactam:
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Imipenem / Cilastatin / Relebactam Formula-
tion

Version: 4.17
Revision Date: 2021/08/27
SDS Number: 67736-00023
Date of last issue: 2020/10/10
Date of first issue: 2015/02/27

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): 86 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 12 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): > 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 11 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 2.7 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 96.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cilastatin:
Biodegradability:
Result: Not readily biodegradable.
Biodegradation: 27 %
Exposure time: 28 d
Method: OECD Test Guideline 301B
Imipenem / Cilastatin / Relebactam Formulation

<table>
<thead>
<tr>
<th>Component</th>
<th>Biodegradability</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipenem</td>
<td>Not readily biodegradable.</td>
<td>OECD Test Guideline 301B</td>
</tr>
<tr>
<td>Biodegradation: 29 %</td>
<td>Exposure time: 28 d</td>
<td></td>
</tr>
<tr>
<td>Cilastatin</td>
<td>Not readily biodegradable.</td>
<td>OECD Test Guideline 314</td>
</tr>
<tr>
<td>Biodegradation: 11.3 %</td>
<td>Exposure time: 28 d</td>
<td></td>
</tr>
</tbody>
</table>

Bioaccumulative potential

**Components:**

- **Cilastatin:**
  - Partition coefficient: n-octanol/water: log Pow: -3.53
- **Imipenem:**
  - Partition coefficient: n-octanol/water: log Pow: < -1
- **Relebactam:**
  - Partition coefficient: n-octanol/water: log Pow: < -2

Mobility in soil

**Components:**

- **Cilastatin:**
  - Distribution among environmental compartments: log Koc: 2.3
- **Relebactam:**
  - Distribution among environmental compartments: log Koc: 2.3

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

**Disposal methods**

- **Waste from residues:** Dispose of in accordance with local regulations.
- **Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class : 9
Packing group : III
Labels : 9

IATA-DGR
UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Imipenem)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 956
Packing instruction (passenger aircraft) : 956
Environmentally hazardous : yes

IMDG-Code
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

GB 6944/12268
UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class : 9
Packing group : III
Labels : 9

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data
15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

16. OTHER INFORMATION

Further information


Date format: yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No
Imipenem / Cilastatin / Relebactam Formula- tion

Version 4.17  Revision Date: 2021/08/27  SDS Number: 67736-00023  Date of last issue: 2020/10/10
          Date of first issue: 2015/02/27

1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-
tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Tem-
perature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Trans-
portation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Sub-
stances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recom-
mendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumu-
lative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, infor-
mation and belief at the date of its publication. The information is designed only as a guidance for
safe handling, use, processing, storage, transportation, disposal and release and shall not be
considered a warranty or quality specification of any type. The information provided relates only
to the specific material identified at the top of this SDS and may not be valid when the SDS mate-
rial is used in combination with any other materials or in any process, unless specified in the text.
Material users should review the information and recommendations in the specific context of their
intended manner of handling, use, processing and storage, including an assessment of the ap-
propriateness of the SDS material in the user’s end product, if applicable.

CN / EN